Early Experience With Eravacycline for Complicated Infections. (2nd March 2020)

• Record Type: Journal Article
• Authors: Alosaimy, Sara; Molina, Kyle C; Claeys, Kimberly C; Andrade, Justin; Truong, James; King, Madeline A; Pullinger, Benjamin M; Huang, Glen; Morrisette, Taylor; Lagnf, Abdalhamid M; Davis, Susan L; Rybak, Michael J
• Is Part Of: Open forum infectious diseases. Volume 7:Number 5(2020)
• Publication Date: 2020-03-02
• Subjects: eravacycline -- multidrug-resistant Enterobacteriaceae -- tetracyclines; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofaa071
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was Klebsiella pneumoniae, and 30-day survival was 74%. Absence of 30-day recurrence and resolution of signs and symptoms of infection were 91% and 57%, respectively. ERV was well-tolerated, with adverse events leading to drug discontinuation in one patient.